CJC-1295 is a growth-hormone-releasing hormone analog with a development status of "preclinical / early human studies". The Institute rates the strength of its published evidence as emerging. A GHRH analog engineered for extended half-life, studied for its ability to raise growth hormone and IGF-1 levels.
The distinction that matters most when reading about CJC-1295 is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Sample sizes in the CJC-1295 literature are small enough that individual studies should be read as hypothesis-generating rather than conclusive. Effect sizes reported in small trials are systematically inflated, and the pattern is well documented across pharmacology generally.
The Institute has independently tested 8 CJC-1295 samples from 7 companies. 100% met their label claims on purity and content. Measured purity ranged from 96.7% to 99.1%, averaging 97.9%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
